Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Abstract
Despite promising advances in breast cancer immunotherapy, augmenting T-cell infiltration has remained a significant challenge. Although neither individual vaccines nor immune checkpoint blockade (ICB) have had broad success as monotherapies, we hypothesized that targeted vaccination against an oncogenic driver in combination with ICB could direct and enable antitumor immunity in advanced cancers.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-0389
Entities
People
- Anthony-Fayez Haddad
- Benjamin G Vincent
- Benjamin K. Ashby
- Chaitanya Acharya
- Charles M. Perou
- Christopher A. Rabiola
- Cong-xiao Liu
- Daniel P. Hollern
- Erika J Crosby
- Gangjun Lei
- Gloria Broadwater
- Herbert Kim Lyerly
- Jeremy Force
- Jonathan H. Shepherd
- Joshua C. Snyder
- Jun-ping Wei
- K-U Wagner
- Lewis A Chodosh
- Michael A. Morse
- Shengjie Chai
- Tao Wang
- Terry Hyslop
- William Muller
- Xiao-yi Yang
- Xiaping He
- Zachary C Hartman
Organizations
- Canadian Institutes of Health Research
- Cancer Research Society
- Duke University
- McGill University
- National Cancer Institute
- Susan G. Komen for the Cure
- United States Department of Defense
- University of North Carolina
- University of Pennsylvania
- Wayne State University